AC Immune SA, a Swiss clinical-stage biopharmaceutical company, has been making waves with its innovative approach to preventing and treating neurodegenerative diseases. Boasting an impressive portfolio of SupraAntigen and Morphomer platforms, the company has taken on the challenge of developing vaccines, antibodies, and small molecules to selectively interact with misfolded proteins in a range of neurodegenerative diseases. Currently, AC Immune is focusing its efforts on Crenezumab, a conformation-specific monoclonal antibody in Phase II clinical studies that has significant potential for treating Alzheimer's disease (AD). The company is also developing ACI-24, an anti-Abeta vaccine candidate that has completed Phase Ib clinical study for Down syndrome and is currently in Phase II clinical study for AD. ACI-35, an anti-Tau vaccine candidate in Phase Ib/2a clinical study, and a Tau-PET imaging tracer in Phase II clinical study are both promising developments in the field. The company is also exploring the use of small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Additionally, AC Immune is making strides in preclinical research and discovery in the field of neurodegenerative diseases, with diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. With several notable license agreements and collaborations to its name, including partnerships with Genentech, Biogen International, Janssen Pharmaceuticals, Life Molecular Imaging, Eli Lilly and Company, and WuXi Biologics, AC Immune is clearly making its mark in the biopharmaceutical industry.
AC Immune's ticker is ACIU
The company's shares trade on the NASDAQ stock exchange
They are based in Lausanne, Switzerland
There are 51-200 employees working at AC Immune
It is https://www.acimmune.com/
AC Immune is in the Healthcare sector
AC Immune is in the Biotechnology industry
The following five companies are AC Immune's industry peers: